TY - JOUR
T1 - Post-Infectious Irritable Bowel Syndrome
AU - Lee, Yeong Yeh
AU - Annamalai, Chandramouli
AU - Rao, Satish S.C.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Purpose of Review: Post-infectious irritable bowel syndrome (PI-IBS) is characterized by persistent abdominal pain and diarrhea, typically following an episode of infectious gastroenteritis. The mechanisms that underlie IBS-D remain elusive, but PI-IBS provides a mechanistic model of this disorder. This review provides an up-to-date appraisal of the pathophysiology, clinical features, and management approaches for PI-IBS. Recent Findings: Disordered immune reactions and release of cytokines with resultant gut inflammation and dysfunction appear to be key features of PI-IBS. Disordered brain-gut-microbiota interactions, type of infecting agent, and host-genetic susceptibility are risk factors but also are reasons for the varying spectrum of clinical severity. Although prognosis is generally good, symptoms and inflammation may persist for a long time. Symptomatic relief with antidiarrheals, antispasmodics, 5HT3 antagonists, mesalamine, probiotics, and low-dose antidepressants remain the primary approaches, but in some difficult cases, a combination of drugs that target the pathophysiology may be helpful. Summary: PI-IBS has many overlapping features with IBS-D and shares similar pathophysiology and management approaches.
AB - Purpose of Review: Post-infectious irritable bowel syndrome (PI-IBS) is characterized by persistent abdominal pain and diarrhea, typically following an episode of infectious gastroenteritis. The mechanisms that underlie IBS-D remain elusive, but PI-IBS provides a mechanistic model of this disorder. This review provides an up-to-date appraisal of the pathophysiology, clinical features, and management approaches for PI-IBS. Recent Findings: Disordered immune reactions and release of cytokines with resultant gut inflammation and dysfunction appear to be key features of PI-IBS. Disordered brain-gut-microbiota interactions, type of infecting agent, and host-genetic susceptibility are risk factors but also are reasons for the varying spectrum of clinical severity. Although prognosis is generally good, symptoms and inflammation may persist for a long time. Symptomatic relief with antidiarrheals, antispasmodics, 5HT3 antagonists, mesalamine, probiotics, and low-dose antidepressants remain the primary approaches, but in some difficult cases, a combination of drugs that target the pathophysiology may be helpful. Summary: PI-IBS has many overlapping features with IBS-D and shares similar pathophysiology and management approaches.
KW - Diarrhea
KW - Gastroenteritis
KW - Inflammation
KW - Irritable bowel syndrome
KW - Pathophysiology
UR - http://www.scopus.com/inward/record.url?scp=85029955034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029955034&partnerID=8YFLogxK
U2 - 10.1007/s11894-017-0595-4
DO - 10.1007/s11894-017-0595-4
M3 - Review article
C2 - 28948467
AN - SCOPUS:85029955034
SN - 1522-8037
VL - 19
JO - Current Gastroenterology Reports
JF - Current Gastroenterology Reports
IS - 11
M1 - 56
ER -